Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - - PowerPoint PPT Presentation

wockhardt limited
SMART_READER_LITE
LIVE PREVIEW

Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - - PowerPoint PPT Presentation

Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q1FY16 Safe Harbor Statement Except for historical information contained herein, statements in this communication, which include words or phrases such


slide-1
SLIDE 1

Wockhardt Limited

Investor Presentation By

  • Dr. Murtaza Khorakiwala

Managing Director Q1FY16

slide-2
SLIDE 2

Safe Harbor Statement

  • Except for historical information contained herein, statements in this communication, which include

words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “August”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions August constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other

  • risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to

reflect events or circumstances after the date thereof.

Investor Presentation August 2015 2

slide-3
SLIDE 3

Introduction to Wockhardt

Key Business Dynamics

slide-4
SLIDE 4

ROW operations Wockhardt Direct

  • perations

USA UK, Ireland, France, Switz. India

Mexico

Wockhardt Today

Investor Presentation August 2015 4

Direct Operations in India, USA and Europe

Multi Ethnic workforce from 21 different Nationalities

slide-5
SLIDE 5

UK Ireland

Wockhardt Today

Investor Presentation August 2015 5

12

Manufacturing Locations globally

Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Baddi Chicago

Formulations APIs 9 sites in India

slide-6
SLIDE 6

Wockhardt Today

Investor Presentation August 2015 6

3 R&D Centers

worldwide

USA / UK & India

slide-7
SLIDE 7

Key Business Update

slide-8
SLIDE 8

Key Business Update

Investor Presentation August 2015 8

  • US FDA has completed inspection in one of the manufacturing facility in Himachal Pradesh

in July, 2015 and no 483 has been issued to the company.

  • US FDA’s inspection of Waluj facility completed during the quarter with minor
  • bservations.
  • The Company’s on going efforts towards compliance measures for Chikalthana and Waluj

facilities continues to be in place.

  • Resumed Supplies to UK from our Chikalthana Facility.
  • Received the coveted Breakthrough discovery (QIDP) status for another NCE product WCK

4873 during the quarter. Previously 2 of its drug WCK 771 and WCK 2349 received QIDP

  • status. QIDP status allows for fast track review by US FDA and also grants a five year

extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.

  • Got approval from US FDA for marketing 5mg/5ml of Oxycodone HCL liquid from MGP.

Oxycodone is used extensively in management of pain, especially in opioid tolerant patients.

  • Filed for 54 patents during the quarter taking the cumulative filings to 2322 and has been

granted 26 patents during the quarter taking the cumulative patents granted to 367.

Regulatory Update Research Update

slide-9
SLIDE 9

Q1FY16 Results

slide-10
SLIDE 10

Sales – Growth of 15% over Q1FY15

Investor Presentation August 2015 10

Rs.crore Growth of 15% in Q1FY16 over Q1FY15

slide-11
SLIDE 11

EBITDA – Growth of 165% over Q1FY15

Investor Presentation August 2015 11

Rs.crore Growth of 165% in Q1FY16 over Q1FY15

slide-12
SLIDE 12

PAT – Growth of 470% over Q1FY15

Investor Presentation August 2015 12

Rs.crore Growth of 470% in Q1FY16 over Q1FY15

slide-13
SLIDE 13

Research – 13.3% of Sales in Q1FY16

Investor Presentation August 2015 13

Growth of 31% in Q1FY16 over Q1FY15

slide-14
SLIDE 14

US Business

Investor Presentation August 2015 14

  • Contributes 20% of Total Revenue.
  • Declines by 21% (26% in $ terms)
  • ver Q1FY15.
  • During the Q1FY16, 5 ANDA’s filed

& 1 approval received cumulative ANDA’s pending for approval is 73.

287 227

  • 200

400

Q1-FY15 Q1-FY16

USA

Rs.cr.

$48 $36

slide-15
SLIDE 15

EU Operations

UK Operations

  • 1 New filing done and 1 New product launched in

Q1FY16.

  • UK operation Grows by 55% (grows by 59% £ terms) in

Q1FY16.

Investor Presentation August 2015 15

Ireland Operations

  • Ireland Declines by 11% (growth of 4% in € terms) in

Q1FY16.

237 368

120 170 220 270 320 370 420 Q1-FY15 Q1-FY16

UK

Rs.cr. £ 23 £ 37 44 39

36 37 38 39 40 41 42 43 44 Q1-FY15 Q1-FY16

Ireland

Rs.cr. € 5 € 6

slide-16
SLIDE 16

India & Emerging Markets

  • India Business Grows by 27% for Q1FY16.
  • 24 new products in Q1FY16 launched in

India.

  • Emerging Market operations grew by

47% in Q1FY16.

Investor Presentation August 2015 16

295 India 375 India

66 EM

97 EM 100 200 300 400 500

Q1FY15 Q1FY16

India & Emerging Markets (EM)

Rs.cr.

slide-17
SLIDE 17

Investor Presentation August 2015 17

For investor updates and communication please visit www.wockhardt.com For Information please contact Arun Khatanhar Tel.: +91 22 71596228 Akhatanhar@wockhardt.com